The objective of this contract is to acquire pharmacologic and toxicologic data on new drugs for the treatment of Cancer and the Acquired Immunodeficiency Syndrome (AIDS) and AIDS-related illnesses. The data will be included in an Investigational New Drug (IND) application to the FDA which is required prior to the initiation of human clinical trials. Level A contract is 46,875 hours over 5 years. Level B contract is 93,750 hours over 5 years. This contract will be awarded at Level A because the laboratory has the capability, expertise and experience to do the amount of work required.
|Holleran, Julianne L; Parise, Robert A; Joseph, Erin et al. (2005) Plasma pharmacokinetics, oral bioavailability, and interspecies scaling of the DNA methyltransferase inhibitor, zebularine. Clin Cancer Res 11:3862-8|
|Glaze, Elizabeth R; Lambert, Amy L; Smith, Adaline C et al. (2005) Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance. Cancer Chemother Pharmacol 56:637-47|
|Lyubimov, Alexander V; Smith, Jeffry A; Rousselle, Serge D et al. (2004) The effects of tetrathiomolybdate (TTM, NSC-714598) and copper supplementation on fertility and early embryonic development in rats. Reprod Toxicol 19:223-33|
|Cheng, Xun; Shin, Young Geun; Levine, Barry S et al. (2003) Quantitative analysis of betulinic acid in mouse, rat and dog plasma using electrospray liquid chromatography/mass spectrometry. Rapid Commun Mass Spectrom 17:2089-92|